Cytomed Therapeutics entered into BRCA with SunAct

CytoMed Therapeutics (GDTC) announced that it has entered into a Business & Research Collaboration Agreement, BRCA, with Mumbai-based SunAct Cancer Institute Private Limited, SunAct, a company incorporated in the Republic of India. The BRCA forms a collaborative effort between CytoMed and SunAct to explore and investigate the safety, tolerability, potency, and efficacy of CytoMed’s proprietary allogeneic gamma delta T cells for the treatment of various cancers in human subjects through clinical research, including a Phase 2 investigator-initiated trial in India. CytoMed and SunAct will be the joint sponsors of the Clinical Trial, working with the medical team in the SunAct Cancer Institute, led by Prof Dr Vijay Patil, a renowned medical oncologist and immunotherapy specialist in India and the founder of SunAct.